A recent study published in Proceedings of the National Academy of Sciences has identified two enzymes — PDIA1 and PDIA5 — as key drivers of prostate cancer survival and treatment resistance. By stabilising the androgen receptor, these enzymes enable tumour cells to grow and withstand current therapies.
Key Points
- Inhibiting PDIA1/PDIA5 destabilises the androgen receptor, resulting in cancer-cell death.
- This approach disrupts tumour signalling pathways and impairs cellular energy production.
- Combining enzyme inhibition with existing therapies such as Enzalutamide significantly enhances treatment response.
- Targeting these enzymes may offer a new strategy to address therapy resistance — a critical challenge in prostate cancer management.
Why It Matters
Prostate cancer remains one of the most common cancers globally. Identifying molecular vulnerabilities like PDIA1 and PDIA5 supports the development of more effective, personalised treatment combinations and may contribute to improved long-term outcomes.
Important Context
These findings come from pre-clinical research. Further studies, including human trials, are necessary to evaluate safety, selectivity and clinical applicability.
Advancing Awareness
Progress will depend on close collaboration across clinical practice, research and industry. Insights like these help shape the future landscape of prostate cancer therapeutics and reinforce the importance of continued innovation in oncology.